ReadSpeaker VoiceLab Powers Sonos Voice Control Custom Voice
17.5.2022 15:00:00 EEST | Business Wire | Press release
ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Sonos, the world’s leading sound experience company, has selected the ReadSpeaker VoiceLab to create a custom voice for Sonos Voice Control, the brand’s voice assistant. Sonos selected VoiceLab, ReadSpeaker’s custom voice production unit, because of the company’s proven experience and expertise in state-of-the-art, AI-driven text-to-speech.
Leading consumer brands are looking to develop their own voice assistants to provide consistently on-brand, personalized and engaged automated customer experiences. Those with a visionary strategy and commitment to consumer privacy, like Sonos, are understanding the broader importance of AI-driven digital voice in helping expand their business and meet consumer needs and expectations, even as they quickly evolve.
The ReadSpeaker VoiceLab managed the development process, including carrying out recordings with Giancarlo Esposito, processing the recorded data, training Deep Neural Networking (DNN) models on that data, and managing quality control, delivery, and all necessary quality assurance steps. Because of the technicality of the voice recordings required to build the custom voice, which requires speech to be delivered in an extremely consistent way that prioritizes precise articulation and style, ReadSpeaker’s VoiceLab experts worked closely with Esposito throughout every stage of the process.
A key challenge in the development of this custom voice was the need for it to comprehend and pronounce non-standard text content that is often found in the music industry. It was also critical that the assistant was able to read artists’ track or album information in numerous languages. The VoiceLab team worked closely with Sonos and Esposito to optimize the speech output for this massively broad domain.
Sonos Voice Control is an entirely new voice experience that delivers fast, accurate hands-free control of your music and your Sonos system with unmatched privacy. Designed with privacy at its core, Sonos Voice Control is the simplest way to control your music, offering complete command of your Sonos system using only your voice. Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available from June 1 in the US and later this year in France on all voice capable Sonos products, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.
“We selected ReadSpeaker to power the custom voice for Sonos Voice Control for a variety of reasons, not least of which was their ability to work closely with us from the development phase all the way through delivery,” said Joseph Dureau, Vice President, Voice Experience, at Sonos. “ReadSpeaker’s approach to custom voice is innovative and extremely thorough – which is exactly what we required for this project – and the company’s dedicated linguistic team has been a critical tool for us throughout this project.”
“As brands become increasingly aware that, much like a visual logo, a custom voice ensures consistently engaging, on-brand interactions across touchpoints, our VoiceLab is developing voices that speak to their brand persona and create unique experiences,” said Roy Lindemann, CMO and CCO EMEA, at ReadSpeaker. “With more consumers leveraging digital voice every day for everything from making purchases to choosing which playlist to listen to, having a custom branded voice is becoming table stakes for delivering a quality, personalized CX in real time. By partnering with Sonos, we are helping to bring yet another brand’s voice to life in an exciting, innovative way.”
Watch the SVC Custom Voice “behind the scenes” video here: https://www.youtube.com/watch?v=vwJ8Ub10arQ
For more information about the ReadSpeaker VoiceLab, visit www.readspeaker.ai/solutions/custom-text-to-speech-tts-voices/.
About ReadSpeaker:
ReadSpeaker is the most trusted independent digital voice partner for global brands, institutions, and organizations. With over 20 years’ experience, ReadSpeaker’s AI-powered text-to-speech solutions and expert assistance enhance the accessibility of digital content and enable more user-friendly and engaging interactions with technology. The company’s flexible cloud and on-premise solutions bring over 110 expressive, humanlike synthetic voices in more than 35 languages to any application or device. The company consistently maintains its uncompromising commitment to data privacy and has so far speech enabled over 10,000 voice applications worldwide.
ReadSpeaker’s digital voice design brand, readspeaker.ai, helps agencies, integrators, and developers to enhance CX and drive sales through consistently engaging, on-brand interactions across touchpoints. For more information, go to readspeaker.ai and follow the company on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005419/en/
Contact information
ReadSpeaker:
Victoria Newell
V2 Communications for ReadSpeaker
readspeaker@v2comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
